[RFA-CA-27-001] Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Description

Titolo: Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) Numero dell'opportunità: RFA-CA-27-001 Stato: aperto (posted) Tipo di opportunità: Discretionary Ente: National Institutes of Health — Department of Health and Human Services Tipo di finanziamento: Grant Categoria: Health Programma (ALN): 93.394 Cancer Detection and Diagnosis Research Pubblicato il: 2026-06-03 Scadenza per le domande: 2026-11-10 Importo massimo per progetto: 150,000 USD Finanziamento totale stimato: 5,100,000 USD Numero di finanziamenti attesi: 20 Cofinanziamento richiesto: no Chi può fare domanda: Special district governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; State governments; Native American tribal governments (Federally recognized); Small businesses; City or township governments; Independent school districts; For profit organizations other than small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; County governments; Native American tribal organizations (other than Federally recognized tribal governments); Private institutions of higher education Altre condizioni di eleggibilità: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Descrizione: Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Contatto: [email protected]

Sectors

Source

Source: grants.gov